NuCana Q2 EPS £(0.12) Vs £(0.10) YoY
NuCana Q2 EPS £(0.12) Vs £(0.10) YoY
As of June 30, 2024, NuCana had cash and cash equivalents of £11.6 million compared to £12.9 million as of March 31, 2024 and £17.2 million at December 31, 2023. NuCana continues to advance its numerous clinical programs and reported a net loss of £7.0 million for the quarter ended June 30, 2024, as compared to a net loss of £5.4 million for the quarter ended June 30, 2023. Basic and diluted loss per ordinary share was £0.12 for the quarter ended June 30, 2024, as compared to £0.10 per ordinary share for the comparable quarter ended June 30, 2023.Key Data Readouts on Track for All Programs in 2024
所有项目的关键数据发布计划于2024年达成
Anticipated Cash Runway into Q1 2025
预计现金储备能够支持至2025年第一季度
EDINBURGH, United Kingdom, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the second quarter ended June 30, 2024 and provided an update on its broad clinical development program with its transformative ProTide therapeutics.
2024年8月15日，英国爱丁堡（GLOBE NEWSWIRE）-- NuCana plc （NASDAQ:NCNA）公布了截至2024年6月30日的第二季度财务业绩并就其变革性的ProTide药物的广泛临床开发计划进行了更新。
As of June 30, 2024, NuCana had cash and cash equivalents of £11.6 million compared to £12.9 million as of March 31, 2024 and £17.2 million at December 31, 2023. NuCana continues to advance its numerous clinical programs and reported a net loss of £7.0 million for the quarter ended June 30, 2024, as compared to a net loss of £5.4 million for the quarter ended June 30, 2023. Basic and diluted loss per ordinary share was £0.12 for the quarter ended June 30, 2024, as compared to £0.10 per ordinary share for the comparable quarter ended June 30, 2023.
截止到2024年6月30日，NuCana的现金及现金等价物为1160万英镑，相比于2024年3月31日的1290万英镑和2023年12月31日的1720万英镑。NuCana继续推进众多临床项目，报告2024年6月30日为季度净亏损700万英镑，相比于2023年6月30日净亏损540万英镑。基本每股普通股和摊薄每股普通股净亏损为£0.12，相比于2023年6月30日可比季度每股普通股净亏损£0.10。
